MiRNAs: Novel molecules in cancer therapy
Journal of Cellular Immunotherapy · 2015
DOI: 10.1016/j.jocit.2015.10.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Immunotherapy, 2015. Verfasst von Mina Lashkarboloki und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
activity of NK cells and suppress IL-2-stimulated NK cell growth signaling in vivo and in vitro.IV-TDEs can also skew monocyte differentiation into DCs toward the generation of myeloid derived suppressor cells and display Transforming Growth Factor-b1 (TGF-b1) mediated suppressive activity on T Lymphocytes in vitro.By eeleasing of vesicular structures, tumor cells can adjust host environment for surviving and progressing in vivo.Another supporting study in mouse models demonstrated that exosomes secreted by murine mammary carcinoma cells and melanoma cells suppressed the differentiation of DCs via inducing IL-6.V-TDEs can participate in drug resistance via several mechanisms.The first mechanism is by drug exportation through the exosome pathway.Ovarian carcinoma cells stably got resistance to the cancer chemotherapy drug cisplatin (CDDP).Exosomes snared cytoplasmic CDDP, and then exported it to exit the cell.To do it, multivesicular bodies fuse with the plasma membrane and leave their content.In addition, exosomes can nullify antibody-based drugs.Exosomes produced by HER2-overexpressing breast carcinoma cell lines that express a full-length HER2 molecule can bind to the HER2 antibody Trastuzumab.Exosomal inhibition of antibody by reducing antibody binding to cancer cells suppresses the effect of Trastuzumab on the proliferation of these cells.On the other hand, due to the similarity of Cl À concentration within exosomes and extracellular fluids, once chemotherapy agent Cisplatin incorporated into exosomes secreted by melanoma cells, it remains in native unhydrated form.VI-Exosomes can be used as biomarkers to monitor the emergence, progression, prognosis of cancer, and efficacy of treatment regimens.Exosomes can be detected in higher concentrations, both in tumor tissue, and the serum and plasma of cancer patients.VII-TDEs displacing a role in tumor progression and metastatic niche formation as mediators of metastasis.They mobilize bone marrow-derived cells (BMDCs) that support tumor vasculogenesis, invasion and metastasis.Furthermore, the presence of melanoma exosomes in lymph nodes induces angiogenic growth factors necessary for melanoma growth and metastasis even in the local absence of tumor cells.In summary, the unique character of exosomes, including their ability to induce antitumor responses, express death ligand and accommodate specific genetic materials, their participating in drug resistance, their stability in circulation, their reproducible detection and, significantly, the fact that they show the properties of cancer cells, indicate they may be used as diagnostic strategies for non-invasive and quick tracing of the pathological condition of cancer patients, as well as therapeutic agents and cancer vaccine for providing viable treatment options.
Zitieren
APA
Lashkarboloki, M., Boozarpour, S., Jorjani, E., Sabouri, H., Fahimi, M., & Gorji, S. S. (2015). MiRNAs: Novel molecules in cancer therapy. Journal of Cellular Immunotherapy. https://doi.org/10.1016/j.jocit.2015.10.025
Vancouver
Lashkarboloki M, Boozarpour S, Jorjani E, Sabouri H, Fahimi M, Gorji SS. MiRNAs: Novel molecules in cancer therapy. Journal of Cellular Immunotherapy. 2015. doi:10.1016/j.jocit.2015.10.025
BibTeX
@article{Lashkarboloki2015,
author = {Lashkarboloki, Mina and Boozarpour, Sohrab and Jorjani, Eisa and Sabouri, Hossein and Fahimi, Masood and Gorji, Simin Siami},
title = {MiRNAs: Novel molecules in cancer therapy},
journal = {Journal of Cellular Immunotherapy},
year = {2015},
doi = {10.1016/j.jocit.2015.10.025}
}
EUVIMED